Mark Erlander, PhD | Chief Scientific Officer
Mark Erlander joined Trovagene in 2013 as Chief Scientific Officer to lead the development of the Company’s Precision Cancer Monitoring® (PCM) technology platform, and to advance Trovagene’s clinical study programs to demonstrate the utility of circulating tumor DNA in the detection and monitoring of oncogene mutations.
Dr. Erlander has more than 20 years of experience directing and leading research for molecular diagnostic programs, with industry expertise in discovery, assay development, clinical study validation, and CLIA laboratory operations for oncology-based molecular diagnostics.
Prior to joining Trovagene, Dr. Erlander served as Chief Scientific Officer at bioTheranostics (a bioMerieux company), AviaraDx and Arcturus, where he lead research and development of diagnostic, prognostic and predictive tests for breast cancer and metastatic cancers that support physicians in the treatment of cancer patients.
Previously, Dr. Erlander was a group leader, and subsequently, a research fellow at the R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson). He was also an assistant member, and postdoctoral fellow, at The Scripps Research Institute in the Department of Molecular Biology.
Dr. Erlander is an accomplished researcher in diagnostics, therapeutics and genomic technologies with over 40 issued U.S. patents. He has co-authored 69 peer-reviewed original articles and 17 review/chapter publications, covering discovery, validation, clinical utility and health economics for molecular diagnostic products.
Dr. Erlander holds a BS degree in Biochemistry from the University of California, Davis; an MS degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles.